恒华科技
1000-9999人
公司优势
恒华科技是一家运用互联网技术和物联网技术，为智能电网提供全生命周期一体化、专业化咨询和信息化服务的高科技企业，已成为中国智能电网信息化领域的领军企业。
凭借强大的软件研发实力、卓越的信息技术服务能力和丰富的工程设计与管理经验，恒华科技在智慧能源、智能交通、智慧环保和智慧城市四大领域，提供软件产品及服务、工程设计与服务、工程总承包/项目管理三大业务，致力于提供全价值链的一体化服务。
恒华科技以北京为基地，在河北、内蒙古、山东、上海、四川、天津、云南、香港等地设有分支机构，业务遍布全国及部分海外市场。
“吸纳人才、发展人才”是恒华科技的人才战略，公司为员工提供了广阔的发展空间和良好的成长环境。您的加入将推动恒华科技的发展，我们为您取得的成功感到骄傲！
公司获得的荣誉包括：2013-2014年度国家规划布局内重点软件企业、国家火炬计划重点高新技术企业、2016年中国智能电网信息化领军企业、2015年北京市新技术新产品、2014年中国地理信息产业百强企业（排名前30）、2014年中国十大创新软件企业、2013年中国优秀测绘工程金奖、2011年德勤高科技高成长中国50强；亚太500强、2011年中国地理信息产业最佳雇主；最具社会责任感雇主。
公司以北京为基地，在上海、成都、昆明、山东等地设有分支机构和技术支持中心，在全国建立了十多个办事处和营销中心，业务遍及全国三十多个省市自治区及部分海外市场。
热招职位
相关职位
20,861+ 岗位更新等你来订阅
一键订阅最新的岗位，每周送达
🎉恭喜你，订阅成功
继续订阅您可以在邮箱中随时取消订阅
专注于新能源与光伏系统设计与安装，我们矢志推动国家实现碳达峰与碳中和目标，积极履行环境保护责任。公司拥有和谐的工作环境，提供极具竞争力的薪酬福利。热忱欢迎具有远大抱负的青年才俊加入，无论是寻求学习成长，还是开启职业生涯，这里都是您的理想选择。
浙江华源颜料股份有限公司作为浙江升华的全资一级子公司，成立于1996年，其麾下拥有德清华博颜料有限公司、德清户田三峰颜料有限公司、广西永福华源科技有限公司以及焦作百利联合颜料有限公司等控股子公司。该公司占地面积达30万平方米，员工总数超过900人，2021年的总产值接近10亿元人民币。其产品销售网络广泛覆盖中国各省份、直辖市、自治区，并远销全球五大洲的80多个国家和地区。
公司专注于开展电子现货交易，亦即大宗农产品的中远期电子交易。这一举措是由国家推行，旨在支持农业发展，优化农产品流通。其交易模式以电子现货仓单为基本单位，依托计算机网络进行跨地区货物交易，并实现统一结算。公司坚决执行国家政策要求，确保所有经营活动遵循相关法律法规。
Guangzhou Runsheng Cytomed Technology Co., Ltd. is a Sino-foreign joint venture biotechnology enterprise dedicated to cell medicine R&D and clinical translational research. The founder and academic leader of the company, Professor Ruan Runsheng, holds a postdoctoral degree from the University of Zurich in Switzerland, is a senior researcher at the National University of Singapore's Department of Medicine, a chief researcher at the Institute of Bioengineering and Nanotechnology of the Singapore Science and Technology Agency, and a member of the European Society of Medical Oncology (ESMO). He has also been included in the US New Century 500 Scientists and the Marquis' Who's Who Yearbook of the United States. Professor Ruan Runsheng has long been committed to the research and development of cellular immunology, with his latest achievement being the Tvac？ tumor personalized precision combined immunotherapy technology.
Founded on September 24, 2019, in Nansha, Guangzhou, the company focuses on exploring and developing the clinical applications of Tvac？ tumor personalized precision combined immunotherapy technology. This technology uses genomics, proteomics, and other omics technologies along with tumor immunology to achieve individualized precision treatment, marking an important direction for future cancer treatments.
Currently, the company has established four platforms: bioinformatics, proteomics, peptide synthesis, and cellular immunity. These platforms are equipped with high-speed local servers and cloud platforms, ultra-high-throughput 106-channel peptide synthesizers, liquid mass spectrometers, PCR instruments, Elispot, flow cytometers, RTCA, and cell culture rooms. These advanced facilities ensure robust support for the screening of new antigens and the development of peptide drugs. The company has built a highly specialized technical R&D team leveraging its platform advantages. Core team members come from prestigious institutions such as the Hong Kong University of Science and Technology, Technical University of Denmark, Stanford University School of Medicine, Harvard Medical School, and Macquarie University in Australia, all holding master's or doctoral degrees. Their expertise spans molecular biology, biochemistry, tumor immunology, clinical medicine, and industrialization.
The company has established strategic partnerships with institutions such as the National University Hospital of Singapore, Guangdong-Hong Kong-Macao Greater Bay Area Postdoctoral Science and Technology Innovation Public Research Center, the First Affiliated Hospital of Sun Yat-sen University, the Second Affiliated Hospital of Guangzhou Medical College, Guangdong Provincial People's Hospital, and Guangzhou First People's Hospital. Tvac？ technology is undergoing steady clinical trials, with smooth progress. Plans are underway to submit an NDA for Tvac？ within the next three years, aiming for formal clinical application in tumor treatment. Simultaneously, the company is advancing other tumor cell therapy R&D and clinical translation projects.
In 2021, the company partnered with the Guangdong-Hong Kong-Macao Greater Bay Area Postdoctoral Science and Technology Innovation Public Research Center to establish a postdoctoral research station, continuously attracting and nurturing high-end biomedical talent. It aims to provide a platform for international researchers pursuing the dream of medical practice.
The company is currently staffed primarily by R&D personnel, with two foreign experts, and maintains a flexible organizational structure and fresh corporate culture. It is a dynamic and energetic cell medicine R&D team with international vision and top-tier standards. Moving forward, the company will closely align with market demands, applying professional technology to medical institutions and patients, and creating an innovative technology platform that integrates scientific development, talent cultivation, and shared benefits.
北京世通仁和数码科技有限公司，规模为50-150人，类型为民营公司，行业为餐饮业。